Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Completed

• Conditions: Pancreatic Cancer Resectable

• Registration Number: NCT06809374
• Lead Sponsor: Kochi University

Brief Summary

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-01
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31
• Status Verified: 2025-01
• Study First Submitted: 2025-01-30
• Study First Submitted QC: 2025-01-30
• Last Update Submitted: 2025-01-30
• Study First Posted: 2025-02-05
• Last Update Posted: 2025-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• radiologically resectable pancreatic cancer patients

Exclusion Criteria

• a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.	within 6 months